Cogent Biosciences Stock Today
| COGT Stock | USD 7.32 0.07 0.95% |
PerformanceVery Weak
| Odds Of DistressLow
|
Cogent Biosciences is selling for under 7.32 as of the 20th of March 2025; that is 0.95 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 7.2. Cogent Biosciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 113.85 M outstanding shares of which 10.8 M shares are currently shorted by private and institutional investors with about 8.22 trading days to cover. More on Cogent Biosciences
Moving against Cogent Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cogent Stock Highlights
| CEO President | Andrew MBA |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Cogent Biosciences (COGT) is traded on NASDAQ Exchange in USA. It is located in 275 Wyman Street, Waltham, MA, United States, 02451 and employs 205 people. Cogent Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 825.41 M. Cogent Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 113.85 M outstanding shares of which 10.8 M shares are currently shorted by private and institutional investors with about 8.22 trading days to cover.
Cogent Biosciences currently holds about 325.56 M in cash with (207.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check Cogent Biosciences Probability Of Bankruptcy
Ownership AllocationThe majority of Cogent Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cogent Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cogent Biosciences. Please pay attention to any change in the institutional holdings of Cogent Biosciences as this could imply that something significant has changed or is about to change at the company.
Check Cogent Ownership Details
Cogent Biosciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cogent Biosciences market risk premium is the additional return an investor will receive from holding Cogent Biosciences long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0018 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | 0.291 | |||
| Treynor Ratio | 0.0636 |
Cogent Stock Against Markets
Cogent Biosciences Corporate Management
| Rachael MD | VP Development | Profile | |
| Sara Saltzman | VP Affairs | Profile | |
| Jessica MD | Chief Officer | Profile | |
| Brad Fell | Senior Chemistry | Profile | |
| Christi Waarich | Senior Relations | Profile | |
| Brad Barnett | Chief Officer | Profile |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.